Goldman Sachs analyst Rajan Sharma maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £16.90.

British drugmaker GSK said on Monday its experimental cancer drug Blenrep in combination with other treatments reduced the ...

Graham Parry, an analyst from Bank of America Securities, maintained the Sell rating on GlaxoSmithKline (GSK – Research Report). The associated ...

News With vaccine hesitancy leading to a rise in measles cases, the FDA's approval of GlaxoSmithKline's venerable vaccine Priorix for sale in the US looks timely.

Massachusetts families are still struggling to find alternatives almost a year after GlaxoSmithKline canceled a widely ...

GlaxoSmithKline is under pressure from shareholders ... becoming the first woman in history to lead a big pharma company. But Sky News reports that shareholders want the incoming CEO to have ...

(Alliance News) - GlaxoSmithKline PLC said on Friday that the US Food & Drug Administration has amended the emergency use authorization fact sheet for sotrovimab, an investigational Covid-19 ...

Stocks in news: Rel Comm, MphasiS ... valuations Nomura Financial Advisory and Securities India has downgraded GlaxoSmithKline Consumer Healthcare to "reduce" from "buy" citing high valuations ...

(Alliance News) - GlaxoSmithKline PLC on Monday afternoon confirmed that it has changed its name to GSK PLC. The west London-based pharmaceutical firm first announced its intent to change its name ...